Rare Cancer Drugs Carry Unique FDA Postmarketing Requirements, Say Scholars

Nearly half of rare oncology drug approvals include postmarketing requirements (PMR) for drug-drug interactions (DDI), a particular concern for cancer patients who are frequently being treated for co-morbidities and palliative care.
Source: Drug Industry Daily